Vector BioPharma
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Vector BioPharma is a Basel, Switzerland-based biopharmaceutical company developing a precision gene delivery platform devoid of viral genes. Launched in 2021 out of Versant Ventures' Ridgeline Discovery Engine with a $30 million Series A commitment, it was led by CEO Lorenz Mayr. Its platform, developed in the lab of protein-engineering pioneer Andreas Plückthun at the University of Zürich, combines high-capacity virus-like particles with designed adapter proteins (the SHREAD platform) to deliver large genetic payloads precisely to target cells — addressing tissue specificity, cargo-size limits and immunogenicity of existing gene-delivery methods.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Founded
Vector BioPharma was founded in Basel, Switzerland out of Versant Ventures' Ridgeline Discovery Engine to develop a precision gene delivery platform based on research from the University of Zürich.
- Series A
Versant Ventures made a $30 million Series A commitment to Vector BioPharma; the company grew to 45 employees, 70% of them PhD-level scientists.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.